Skip to main content
Signal8
Launch Terminal

CRESCENT BIOPHARMA, INC. (CBIO)

Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Crescent Biopharma, Inc. logo

Crescent Biopharma, Inc.

NASDAQ:CBIOHealthcare
-4.19%$13.48
AH$13.67+1.41%vs close
Mkt Cap$500.74M
Float20.86M
O/S37.15M
Vol
$ Vol
RVOL
Inst Own79.5%
SI21.2%
Earnings
Dilution
Crescent Biopharma, Inc. logoNASDAQ:CBIO$13.48-4.19%
FormDescription
13G
Beneficial Ownership Report
8-K
8.01
2
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
S-8
SEC Filing
1
144
Notice of Proposed Sale of Securities
144
Notice of Proposed Sale of Securities
144
Notice of Proposed Sale of Securities
144
Notice of Proposed Sale of Securities
13G/A
Beneficial Ownership Report (Amended)
EFFECT
Notice of Effectiveness
POS AM
Post-Effective Amendment
424B3
Prospectus
3
10-Q
Quarterly Report
3
8-K
2.02,9.01
13D/A
Beneficial Ownership Report (Active, Amended)
4
OWNERSHIP DOCUMENT
8-K
8.01,9.01
424B5
Prospectus Supplement
4
8-K
2.02

1-25 of 676

…